Overall Survival With Palbociclib and Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer

[Hazelgreen]

Published in Oncology and Journal Scan / Research · September 06, 2022

This updated exploratory analysis of the PALOMA-3 study showed superior overall survival (OS) outcomes with palbociclib plus fulvestrant compared with fulvestrant alone in patients with HR+/HER2− advanced breast cancer who had progressed on prior endocrine therapy.

"The median OS [95% confidence interval (CI)] was 34.8 months (28.8-39.9) in the palbociclib group and 28.0 months (23.5-33.8) in the placebo group (stratified hazard ratio, 0.81; 95% CI, 0.65-0.99). The 6-year OS rate (95% CI) was 19.1% (14.9-23.7) and 12.9% (8.0-19.1) in the palbociclib and placebo groups, respectively. Favorable OS with palbociclib plus fulvestrant compared with placebo plus fulvestrant was observed in most subgroups, particularly in patients with endocrine-sensitive disease, no prior chemotherapy for ABC and low circulating tumor fraction and regardless of ESR1, PIK3CA, or TP53 mutation status. No new safety signals were identified."

[love2golfwell]

Thank you for sharing this information! It sounds very promising. You always post such great research and articles. I appreciate that. Sending hugs.

[Hazelgreen in reply to love2golfwell]

Thanks for the encouragement and hugs! Since I have access to oncology practice updates, I try to share any that I think someone might find helpful or encouraging. XOX, Cindy

[love2golfwell in reply to Hazelgreen]

You are welcome. I love to read current research and articles about new treatments for MBC or positive results for existing treatments. It gives me hope.

[michelangelina]

Thank you for sharing this. I am at 4 1/2 years on ibrance/letrozole, with no signs of progression thus far. I am planning on beating that 6 year overall survival rate!

[Hazelgreen in reply to michelangelina]

Since you are already 75% there, I'm sure you will likely do that and more! Best of wishes, Cindy